October Newsletter                          Gentronix Logo
New Publications and Japanese Contract
October 2012
In This Issue
Welcome
BlueScreen HC First Publication
Independent evaluation of GreenScreen HC published by Galderma
Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
Give us your opinion
Join Our Mailing List!
Quick Links
Welcome 

October Already!

With the end of the Olympics, the Paralympics and the wettest summer in the UK for a hundred years, it's time to look to the future. The last twelve months have been good for Gentronix: we have expanded sales in existing markets and entered into new ones; both in terms of industry sector, and geography (See First Japanese contract below)

Nor have we, nor our partners, been standing still on the scientific side either. In this newsletter we are highlighting the first journal publication on BlueScreen™ HC, as well as an independent evaluation of GreenScreen™ HC by Dermatology company Galderma.

Finally we want to take this opportunity in these newsletters to find out what you think, so we are asking you to tell us what other assays you would like Gentronix to offer in the future. It only takes a few seconds, so please help us to continue to support you.

Thank you for your support and we look forward to continuing to work with you in the coming year.

The Gentronix Team.

BlueScreen HC First Publication

The first paper on the use of BlueScreen HC has been accepted for publication by the Journal of Biomolecular Screening.

Development of a high-throughput Gaussia luciferase reporter assay for the activation of the GADD45a gene by mutagens, promutagens, clastogens, and aneugens., C. Hughes,  A. Rabinowitz, M. Tate, L. Birrell, J. Allsup, N. Billinton, R. M. Walmsley.
An e-publication (ahead of print) can be sourced from here.

The paper describes the development and validation of the BlueScreen HC assay in which expression of the GADD45a gene is linked to Gaussia luciferase with a luminescent, rather than fluorescent, reporter, thereby eliminating problems due to autofluorescence.

The conclusion of the paper is that BlueScreen HC was as effective as GreenScreen HC in producing positive results for all classes of genotoxic carcinogen, and negative results for all non-genotoxins tested.

Other papers on BlueScreen, both by Gentronix and by independent organisations, are in the pipeline and will be announced in future newsletters and on the website.
Contact us to find out more about BlueScreen.

 Independent evaluation of GreenScreen published by Galderma

 

French Dermatology company Galderma has published a paper on the evaluation of GreenScreen HC in the Journal of Applied Toxicology.
 
Evaluation of the GADD45α-GFP GreenScreen HC assay for rapid and reliable in vitro early genotoxicity screening., A.P. Luzy,N. Orsini, J.M. Linget, G. Bouvier.

An e-publication (ahead of print) can be sourced from here.

In the paper, 22 of Galderma's proprietary compounds were tested using GreenScreen HC, the SOS-ChromoTest and Mini-Ames. A further 40 characterised compounds were also tested. With the proprietary compounds the study concluded that GreenScreen HC renders the SOS-ChromoTest obsolete for in vitro screening. GreenScreen confirmed all results of the mini-Ames test (100%) and demonstrated 82% concordance with the micronucleus test.
The conclusion of the paper is that GreenScreen HC "appears to be a reproducible, robust, specific and sensitive test for genotoxicity screening".

Contact us to find out how GreenScreen HC can help with early screening.

Gentronix signs first Japanese contracted screening collaboration with Kowa

Kowa Company Ltd. Logo

Gentronix Ltd. has agreed the company's first contracted screening project in Japan, with a major Japanese pharmaceutical manufacturer; Kowa Company, Ltd.

 Under the agreement, Gentronix will conduct genotoxicity screening of compounds for Kowa for use in selected undisclosed therapeutic products in its development pipeline.  

"Gentronix is delighted to be working with Kowa in the Japanese market. We believe that the Gentronix GreenScreen assay with its outstanding specificity, high sensitivity and low compound requirement, is an ideal assay, as an early screen, to assist medicinal chemists make high quality compound decisions, improve attrition rates and avoid the late stage failure of drug candidates." (John Nicholson, Gentronix CEO).

Kowa Company, Ltd.(KCL) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, it is actively engaged in various manufacturing and commercial activitiesin many sectors, including pharmaceuticals, life sciences, information technology, textiles, machinery and various consumer products.

 KCL's pharmaceutical division was founded in 1947, and is focused on cardiovascular therapeutics, with Japan domestic sales of the company's flagship product, pitavastatin (known as LIVALO, LIVAZO and ALIPZA in different markets) totaling JP\50 billion (approximately US$630 million) for 2011.

 

For the full press release, see www.gentronix.co.uk

Contact us to find out how GreenScreen HC can help with early screening

Give Us Your Opinion...

We would like to have your feedback on the issue of future assaysl

What assays would you be interested to see Gentronix develop in the future?

October 2012 Newsletter Question

 

 

Gentronix provides services and solutions that help organisations reduce attrition rates and ensure safer products across a wide range of chemistry driven industries. Our focus is on providing better hazard identification assays and services for genotoxicity through use of GreenScreenŽ HC and BlueScreen™ HC human cell assay technology and a range of complementary in vitro genotoxicity assays. Our proprietary assays are designed for use much earlier in drug and compound discovery than the standard battery of genotoxicity tests and provide positive results that are more accurately predictive of in vivo risk than the current in vitro mammalian assays.

 

See all that we do at www.gentronix.co.uk